To the Editor Dr Hernandez and colleagues1 found that list and net prescription drug prices have increased out of proportion to inflation, and that the gap between list and net prices has widened. Most prominently, among non-Medicaid patients (who are mostly covered by Medicare Part D or commercial insurance plans), rebates and other price concessions increased from 23% in 2007 to 51% in 2018. The authors used estimates of discounts (including manufacturer rebates) calculated by SSR Health, which uses a proprietary algorithm to estimate net prices by dividing publicly reported manufacturer revenue by the volume of filled prescriptions for each branded drug.
Rome BN, Feldman WB, Kesselheim AS. Drug Prices, Rebates, and Discounts. JAMA. 2020;324(4):399. doi:10.1001/jama.2020.7983
Coronavirus Resource Center
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: